Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumours. A review.

Oxygen deficient hypoxic cells, which are resistant to sparsely ionising radiation, have now been identified in most animal and some human solid tumours and will influence the response of those tumours to radiation treatment. This hypoxia can be either chronic, arising from an oxygen diffusion limitation, or acute, resulting from transient stoppages in microregional blood flow. Although clinical attempts to overcome hypoxia have met with some success, the results have been far from satisfactory, and efforts are still being made to find better methods. Extensive experimental studies, especially in the last decade, have shown that nicotinamide and structurally related analogs can effectively sensitise murine tumours to both single and fractionated radiation treatments and that they do so in preference to the effects seen in mouse normal tissues. The earliest studies suggested that this enhancement of radiation damage was the result of an inhibition of the repair mechanisms, as was well documented in vitro. However, recent studies in mouse tumours have shown that the primary mode of action actually involves a reduction in tumour hypoxia. More specifically, these drugs prevent transient cessations in blood flow, thus inhibiting the development of acute hypoxia. This novel discovery led to the suggestion that the potential role of these agents as radiosensitizers would be when combined with treatments that overcame chronic hypoxia. The first attempt to demonstrate this combined nicotinamide with hyperthermia and found that the enhancement of radiation damage by both agents together was greater than that seen with each agent alone. Similar results were later seen for nicotinamide combined with a perfluorochemical emulsion, carbogen breathing, and pentoxifylline, and in all these studies the effects in tumours were always greater than those seen in appropriate normal tissues. Of all the analogs, it is nicotinamide itself which has been the most extensively studied as a radiosensitizer in vivo and the one that shows the greatest effect in animal tumours. It is also an agent that has been well established clinically for the treatment of a variety of disorders, with daily doses of up to 6 g being considered reasonably safe and associated with a low incidence of side effects. This human dose is equivalent to 100-200 mg/kg in mice and such doses will maximally sensitize murine tumours to radiation. These findings have now resulted in phase I/II clinical trials of nicotinamide, in combination with carbogen breathing, as a potential radiosensitizing treatment.

[1]  A. Rojas Radiosensitization with normobaric oxygen and carbogen. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  W. Mcdermott,et al.  Pyrazinamide-isoniazid in tuberculosis. , 1954, American review of tuberculosis.

[3]  M. Horsman,et al.  Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. , 1991, British Journal of Cancer.

[4]  D. Chaplin,et al.  Intermittent blood flow in a murine tumor: radiobiological effects. , 1987, Cancer research.

[5]  C. Song,et al.  Improved tumour oxygenation and radiosensitization by combination with nicotinamide and pentoxifylline. , 1993, International journal of radiation biology.

[6]  O. Hayaishi,et al.  Chapter 1 – Poly- and Mono(ADP-ribosyl)ation Reactions: Their Significance in Molecular Biology , 1982 .

[7]  R. Pero,et al.  Comparison of low dose nicotinamide versus benzamide, administered per os, as radiosensitizers in a C3H mammary carcinoma. , 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  P. Vaupel,et al.  Nicotinamide exerts different acute effects on microcirculatory function and tissue oxygenation in rat tumors. , 1993, International journal of radiation oncology, biology, physics.

[9]  S. B. Field,et al.  Physics and technology of hyperthermia , 1987 .

[10]  M. Burton,et al.  Manipulation of experimental rat and rabbit liver tumor blood flow with angiotensin II. , 1985, Cancer research.

[11]  M. Guichard,et al.  Nicotinamide and carbogen: relationship between pO2 and radiosensitivity in three tumour lines. , 1994, International journal of radiation biology.

[12]  G. Steel,et al.  The response of murine stem spermatogonia to radiation combined with 3-aminobenzamide. , 1987, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[13]  J. Overgaard,et al.  Importance of nicotinamide dose on blood pressure changes in mice and humans. , 1994, International journal of radiation oncology, biology, physics.

[14]  J. Hanley,et al.  Carbogen breathing during radiation therapy-the Radiation Therapy Oncology Group Study. , 1979, International journal of radiation oncology, biology, physics.

[15]  C. Chao,et al.  The Effect of Niacinamide on Cerebral Circulation , 1960, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[16]  W. Kaelin,et al.  Effect of verapamil on malignant tissue blood flow in SMT-2A tumor-bearing rats. , 1982, Cancer research.

[17]  R K Jain,et al.  Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. , 1989, Cancer research.

[18]  C. Song Effect of local hyperthermia on blood flow and microenvironment: a review. , 1984, Cancer research.

[19]  J. D. de Vries,et al.  Determination of nicotinamide in human plasma and urine by ion-pair reversed-phase high-performance liquid chromatography. , 1980, Journal of chromatography.

[20]  R. Jain,et al.  Nicotinamide can lower tumor interstitial fluid pressure: mechanistic and therapeutic implications. , 1992, Cancer research.

[21]  H. Utsumi,et al.  Inhibitors of poly (ADP-ribose) synthesis enhance radiation response by differentially affecting repair of potentially lethal versus sublethal damage. , 1984, The British journal of cancer. Supplement.

[22]  O. S. Nielsen,et al.  Biological Basis for Rational Design of Clinical Treatment with Combined Hyperthermia and Radiation , 1987 .

[23]  D. M. Brown,et al.  Preferential tumor radiosensitization by analogs of nicotinamide and benzamide. , 1986, International journal of radiation oncology, biology, physics.

[24]  L. Mosher Nicotinic acid side effects and toxicity: a review. , 1970, The American journal of psychiatry.

[25]  D. Hirst,et al.  Chlorophenoxy acetic acid derivatives as hemoglobin modifiers and tumor radiosensitizers. , 1989, International journal of radiation oncology, biology, physics.

[26]  J. Moore,et al.  The constant low oxygen concentration in all the target cells for mouse tail radionecrosis. , 1982, Radiation research.

[27]  M. Horsman,et al.  Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. , 1987, Radiation research.

[28]  E. Ben-hur,et al.  Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. , 1985, Cancer Research.

[29]  D. Hirst,et al.  The modification of blood flow in tumours and their supplying arteries by nicotinamide. , 1995, Acta oncologica.

[30]  S. Shall Chapter 29 – ADP-Ribose in DNA Repair , 1982 .

[31]  V. Lassmann-Vague,et al.  NICOTINAMIDE MAY EXTEND REMISSION PHASE ININSULIN-DEPENDENT DIABETES , 1987, The Lancet.

[32]  J. Hendry Radionecrosis of normal tissue: studies on mouse tails. , 1978, International journal of radiation biology and related studies in physics, chemistry, and medicine.

[33]  B. Durkacz,et al.  The effect of inhibition of (ADP-ribose)n biosynthesis on DNA repair assayed by the nucleoid technique. , 1981, European journal of biochemistry.

[34]  D. Martin,et al.  Clinical experience with 6-aminonicotinamide. , 1961, Cancer research.

[35]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[36]  M. R. Purnell,et al.  Novel inhibitors of poly(ADP-ribose) synthetase. , 1980, The Biochemical journal.

[37]  M. Stratford,et al.  Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. , 1993, British Journal of Cancer.

[38]  H. Reinhold,et al.  Oxygenation and reoxygenation in 'sandwich' tumours. , 1977, Bibliotheca anatomica.

[39]  J. Overgaard,et al.  Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  S. Taylor,et al.  Clinical use of 6‐aminonicotinamide in patients with disseminated neoplastic disease , 1961, Cancer.

[41]  M. Trotter,et al.  Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. , 1990, Journal of the National Cancer Institute.

[42]  J. Henk Does hyperbaric oxygen have a future in radiation therapy? , 1981, International journal of radiation oncology, biology, physics.

[43]  R. Hill,et al.  The importance of the pre-irradiation breathing times of oxygen and carbogen (5% CO2: 95% O2) on the in vivo radiation response of a murine sarcoma. , 1977, International journal of radiation oncology, biology, physics.

[44]  R. Pero,et al.  Radiosensitization effects of nicotinamide on malignant and normal mouse tissue. , 1985, Cancer Research.

[45]  H. Zackheim Topical 6-aminonicotinamide plus oral niacinamide therapy for psoriasis. , 1978, Archives of dermatology.

[46]  D. Hirst,et al.  Blood flow modification by nicotinamide and metoclopramide in mouse tumours growing in different sites. , 1993, British Journal of Cancer.

[47]  J. Overgaard,et al.  Tumour radiosensitization by nicotinamide: is it the result of an improvement in tumour oxygenation? , 1994, Advances in experimental medicine and biology.

[48]  J. Boyer,et al.  Hepatic toxicity from large doses of vitamin B3 (nicotinamide). , 1973, The New England journal of medicine.

[49]  G. Adams,et al.  The measurement of radiosensitizer-induced changes in mouse tumor metabolism by 31P magnetic resonance spectroscopy. , 1991, International journal of radiation oncology, biology, physics.

[50]  D. Chaplin,et al.  Acute hypoxia in tumors: implications for modifiers of radiation effects. , 1986, International journal of radiation oncology, biology, physics.

[51]  N. Bleehen,et al.  Effects of the radiosensitising agent nicotinamide on relative tissue perfusion and kidney function in C3H mice. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[52]  L. Karlsson,et al.  Influence of vasoactive drugs and ischaemia on intra-tumour blood flow distribution. , 1978, European journal of cancer.

[53]  J. Overgaard,et al.  The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo. , 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[54]  D. Hirst,et al.  Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients. , 1984, British Journal of Cancer.

[55]  J. Lunec,et al.  Post-irradiation sensitization with the ADP-ribosyltransferase inhibitor 3-acetamidobenzamide. , 1984, The British journal of cancer. Supplement.

[56]  J. Hendry Quantitation of the radiotherapeutic importance of naturally-hypoxic normal tissues from collated experiments with rodents using single doses. , 1979, International journal of radiation oncology, biology, physics.

[57]  J. Preiss,et al.  Specific inhibition of poly adpribose polymerase by thymidine and nicotinamide in HeLa cells , 1971, FEBS letters.

[58]  S. Dische,et al.  Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[59]  O. S. Nielsen,et al.  THE ROLE OF TISSUE ENVIRONMENTAL FACTORS ON THE KINETICS AND MORPHOLOGY OF TUMOR CELLS EXPOSED TO HYPERTHERMIA * , 1980, Annals of the New York Academy of Sciences.

[60]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[61]  J. Overgaard,et al.  The importance of determining necrotic fraction when studying the effect of tumour volume on tissue oxygenation. , 1995, Acta oncologica.

[62]  A. Nobin,et al.  Effects of catecholamines on cardiovascular response and blood flow distribution to normal tissue and liver tumors in rats. , 1980, Cancer research.

[63]  G. Denardo,et al.  Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. , 1972, Cancer research.

[64]  Peter D. Wagner,et al.  Oxygen Transport to Tissue XVI , 2012, Advances in Experimental Medicine and Biology.

[65]  C. Song,et al.  Increases in tumor response by pentoxifylline alone or in combination with nicotinamide. , 1992, International journal of radiation oncology, biology, physics.

[66]  S. Young,et al.  TRYPTOPHAN-NICOTINAMIDE COMBINATION IN DEPRESSION , 1977, The Lancet.

[67]  A. Rojas ARCON: accelerated radiotherapy with carbogen and nicotinamide. , 1992, BJR supplement.

[68]  M. Trotter,et al.  Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide. , 1990, British Journal of Cancer.

[69]  R. Pero,et al.  Effect of hyperthermia and/or nicotinamide on the radiation response of a C3H mammary carcinoma. , 1989, European journal of cancer & clinical oncology.

[70]  S. Rockwell,et al.  Modulation of tumor oxygenation and radiosensitivity by a perfluorooctylbromide emulsion. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[71]  J. Collier,et al.  A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. , 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[72]  J. Overgaard,et al.  Mechanism for the reduction of tumour hypoxia by nicotinamide and the clinical relevance for radiotherapy. , 1989, Biomedica biochimica acta.

[73]  J. Overgaard,et al.  Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. , 1990, Cancer research.

[74]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[75]  G. H. Greenbaum An evaluation of niacinamide in the treatment of childhood schizophrenia. , 1970, The American journal of psychiatry.

[76]  Duane F. Bruley,et al.  Oxygen Transport to Tissue XV , 1994, Advances in Experimental Medicine and Biology.

[77]  D. Martin,et al.  Radiotherapy and adjuvant combination chemotherapy (6-aminonicotinamide and 6-mercaptopurine). , 1958, Cancer research.

[78]  R. Jirtle,et al.  Chemical modification of tumour blood flow. , 1988, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[79]  H. Lehmann,et al.  Nicotinic acid as adjuvant therapy in newly admitted schizophrenic patients. , 1970, Canadian Medical Association journal.

[80]  J. Folkman The vascularization of tumors. , 1976, Scientific American.

[81]  C. Coleman,et al.  Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. , 1988, Journal of the National Cancer Institute.

[82]  P. Kristjansen,et al.  Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice. , 1992, International journal of radiation oncology, biology, physics.

[83]  D. Siemann,et al.  Manipulations in the oxygen transport capacity of blood as a means of sensitizing tumors to radiation therapy. , 1989, International journal of radiation oncology, biology, physics.

[84]  J. Fowler,et al.  The effect of anaesthetics on blood perfusion in transplanted mouse tumours. , 1975, British Journal of Cancer.

[85]  A. Rademaker,et al.  Effects of megavitamin therapy on children with attention deficit disorders. , 1984, Pediatrics.

[86]  S. Rockwell,et al.  Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. , 1984, International journal of radiation oncology, biology, physics.

[87]  J. Brown,et al.  Mechanism of action of the selective tumor radiosensitizer nicotinamide. , 1988, International journal of radiation oncology, biology, physics.

[88]  S. Shall Proceedings: Experimental manipulation of the specific activity of poly(ADP-ribose) polymerase. , 1975, Journal of biochemistry.

[89]  J. Haveman,et al.  The relevance of tumour pH to the treatment of malignant disease. , 1984, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[90]  M. Horsman,et al.  The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[91]  D. M. Brown,et al.  The influence of inhibitors of poly (ADP-ribose) polymerase on X-ray-induced potentially lethal damage repair. , 1984, The British journal of cancer. Supplement.

[92]  R. Pero,et al.  Normal tissue reactions in mice after combined treatment with metoclopramide and ionizing radiation. , 1992, Acta oncologica.

[93]  R. Jirtle,et al.  Effects of several vasoactive drugs on the vascular resistance of MT-W9B tumors in W/Fu rats. , 1978, Cancer research.

[94]  S. Shall ADP-ribosylation reactions. , 1995, Biochimie.

[95]  J. Debatin,et al.  Selective drug-induced reduction of blood flow in tumor transplants. , 1985, International journal of radiation oncology, biology, physics.

[96]  J. Overgaard Sensitization of hypoxic tumour cells--clinical experience. , 1989, International journal of radiation biology.

[97]  J. Brown,et al.  Keynote address: hypoxic cell radiosensitizers: where next? , 1989, International journal of radiation oncology, biology, physics.

[98]  S. Rockwell Use of a perfluorochemical emulsion to improve oxygenation in a solid tumor. , 1985, International journal of radiation oncology, biology, physics.

[99]  D. Hawkins Treatment of schizophrenia based on the medical model. , 1968 .

[100]  K. Haustermans,et al.  Influence of combined use of nicotinamide and carbogen on rat spinal cord radiation tolerance. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[101]  J. Miyakoshi,et al.  Effects of m-aminobenzamide on the response of Chinese hamster cells to hyperthermia and/or radiation. , 1985, Radiation research.

[102]  J. Overgaard,et al.  The combination of nicotinamide and carbogen breathing to improve tumour oxygenation prior to radiation treatment. , 1994, Advances in experimental medicine and biology.

[103]  M. Horsman Carbogen and nicotinamide: expectations too high? (response to J. Martin Brown) , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[104]  G. Adams Radiosensitizers: a conference preview. , 1984, International journal of radiation oncology, biology, physics.

[105]  M. Shils,et al.  Quantitative biochemical differences between tumor and host as a basis for cancer chemotherapy. V. Niacin and 6-aminonicotinamide. , 1957, Cancer research.

[106]  J. Gross,et al.  Dynamics of microvascular flow in implanted mouse mammary tumours. , 1977, Bibliotheca anatomica.

[107]  R. Henriksson,et al.  Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). , 1994, Acta oncologica.

[108]  C. Koch,et al.  Binding of misonidazole to EMt6 and V79 spheroids. , 1982, International journal of radiation oncology, biology, physics.

[109]  H. Utsumi,et al.  Inhibitors of poly(ADP-ribose) synthesis enhance X-ray killing of log-phase Chinese hamster cells. , 1984, Radiation research.

[110]  J. Brown,et al.  Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. , 1989, Radiation research.

[111]  G. Steel,et al.  Basic clinical radiobiology for radiation oncologists , 1993 .

[112]  P. Hees,et al.  Assessment of changes in murine tumor oxygenation in response to nicotinamide using 19F NMR relaxometry of a perfluorocarbon emulsion , 1993, Magnetic resonance in medicine.

[113]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[114]  J. Overgaard,et al.  Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status. , 1989, International journal of radiation oncology, biology, physics.

[115]  M. Horsman,et al.  Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time. , 1993, British Journal of Cancer.

[116]  H. Pohl-Markl,et al.  Treatment of polymorphous light eruption with nicotinamide: a pilot study , 1986, The British journal of dermatology.

[117]  J. Brown,et al.  Pharmacological modification of tumor blood flow: lack of correlation between alteration of mean arterial blood pressure and changes in tumor perfusion. , 1992, International journal of radiation oncology, biology, physics.

[118]  R. Sutherland,et al.  On the nature of the radiobiologically hypoxic fraction in tumors. , 1980, International journal of radiation oncology, biology, physics.

[119]  I. Szumiel,et al.  ADP-ribosylation and post-irradiation cellular recovery in two strains of L5178Y cells. , 1984, The British journal of cancer. Supplement.

[120]  T L Phillips,et al.  Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. , 1993, Radiation research.

[121]  J M Brown,et al.  Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. , 1979, The British journal of radiology.

[122]  J. Hendry,et al.  Care with radiosensitizers. , 1978, The British journal of radiology.

[123]  J. Brown Carbogen and nicotinamide: expectations too high? , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[124]  C. Skidmore,et al.  The enhancement of cytotoxicity of N-methyl-N-nitrosourea and of gamma-radiation by inhibitors of poly(ADP-ribose) polymerase. , 1980, European journal of biochemistry.

[125]  D. Hirst,et al.  Calcium antagonists as radiation modifiers: site specificity in relation to tumor response. , 1989, International journal of radiation oncology, biology, physics.

[126]  F. Scheler,et al.  CLOFIBRATE-INDUCED MYOPATHY SYNDROME , 1976, The Lancet.

[127]  J. Brown,et al.  Structure-activity relationships for tumour radiosensitization by analogues of nicotinamide and benzamide. , 1991, International journal of radiation biology.

[128]  J. Ranstam,et al.  Radiosensitizing effects of nicotinamide on a C3H mouse mammary adenocarcinoma. A study on per os drug administration. , 1986, Acta radiologica. Oncology.

[129]  R. Pero,et al.  Metoclopramide enhances the effect of ionizing radiation on xenografted squamous cell carcinoma of the head and neck. , 1990, International journal of radiation oncology, biology, physics.

[130]  O. Hayaishi,et al.  Adp-Ribosylation Reactions: Biology and Medicine , 1982 .

[131]  J. Overgaard,et al.  Overcoming tumour radiation resistance resulting from acute hypoxia. , 1992, European journal of cancer.

[132]  M. Horsman Hypoxia in Tumours: Its Relevance, Identification, and Modification , 1993 .

[133]  David R. Woerner,et al.  Oxygen, oxygen plus carbon dioxide, and radiation therapy of a mouse mammary carcinoma , 1972, Cancer.

[134]  R. Fieve,et al.  Letter: How blind is the double-blind?: an assessment in a lithium-prophylaxis study. , 1974, Lancet.

[135]  K. Hori,et al.  A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. , 1981, Journal of the National Cancer Institute.

[136]  J. Overgaard,et al.  Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing. , 1994, Acta oncologica.

[137]  C. Song,et al.  The oxygenation of murine tumor isografts and human tumor xenografts by nicotinamide. , 1992, Radiation research.

[138]  P. Vaupel,et al.  Effect of injectable or inhalational anesthetics and of neuroleptic, neuroleptanalgesic, and sedative agents on tumor blood flow. , 1988, Radiation research.

[139]  C. W. Hastings,et al.  Reactions to niacinamide. , 1981, Journal of the American Academy of Dermatology.